A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs CRS 207 (Primary) ; Nivolumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms STELLAR
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research.